Status:
COMPLETED
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
Lead Sponsor:
St. Jude Children's Research Hospital
Conditions:
Hodgkin's Lymphoma
Eligibility:
All Genders
Up to 21 years
Phase:
PHASE2
Brief Summary
The main purpose of this protocol is to estimate the percentage of patients with intermediate risk Hodgkin lymphoma who will survive free of disease (Event-free survival) for three years after treatme...
Detailed Description
Treatment Plan Description: Adriamycin 25 mg/m2 IV Day 1 of weeks 1, 3, 5, 7, 9, 11 Vinblastine 6 mg/m2 IV Day 1 of weeks 1, 3, 5, 7, 9, 11 Nitrogen Mustard 6mg/m2 IV on Day 1 of weeks 1, 5, and 9 ...
Eligibility Criteria
Inclusion
- Patient is less than or equal to 21 years of age
- Patient has a confirmed diagnosis of previously untreated Hodgkin lymphoma
- Has Ann Arbor stage IB, IIIA, or IA/IIA with extranodal extension, multiple nodal involvement (3 or more sites), or bulky mediastinal adenopathy.
Exclusion
- Patients with favorable risk features
- Patients with unfavorable risk features
- Patients who have received prior therapy for Hodgkin lymphoma.
Key Trial Info
Start Date :
July 20 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 15 2022
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT00352027
Start Date
July 20 2006
End Date
November 15 2022
Last Update
September 22 2023
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University Medical Center
Palo Alto, California, United States, 94304
2
Rady Children's Hospital San Diego
San Diego, California, United States, 92123
3
Maine Children's Medical Center
Portland, Maine, United States, 04102-3175
4
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114